BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee SM, Lee JM, Ahn SJ, Kang H, Yang HK, Yoon JH. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium–enhanced MRI. Radiology 2019;292:655-63. [DOI: 10.1148/radiol.2019182867] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Lv K, Cao X, Dong Y, Geng D, Zhang J. CT/MRI LI-RADS version 2018 versus CEUS LI-RADS version 2017 in the diagnosis of primary hepatic nodules in patients with high-risk hepatocellular carcinoma. Ann Transl Med 2021;9:1076. [PMID: 34422988 DOI: 10.21037/atm-21-1035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Bae JS, Lee DH, Lee SM, Suh KS, Lee KW, Yi NJ, Lee KB, Kim H, Han JK. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplantation According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma. AJR Am J Roentgenol 2022. [PMID: 35138137 DOI: 10.2214/AJR.21.27186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li L, Hu Y, Han J, Li Q, Peng C, Zhou J. Clinical Application of Liver Imaging Reporting and Data System for Characterizing Liver Neoplasms: A Meta-Analysis. Diagnostics (Basel) 2021;11:323. [PMID: 33671158 DOI: 10.3390/diagnostics11020323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Ichikawa S, Isoda H, Shimizu T, Tamada D, Taura K, Togashi K, Onishi H, Motosugi U. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study. Eur Radiol 2020;30:5992-6002. [PMID: 32500195 DOI: 10.1007/s00330-020-06972-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Chen J, Kuang S, Zhang Y, Tang W, Xie S, Zhang L, Rong D, He B, Deng Y, Xiao Y, Shi W, Fowler K, Wang J, Sirlin CB. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI. Abdom Radiol (NY) 2021;46:1530-42. [PMID: 33040166 DOI: 10.1007/s00261-020-02790-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Wang Y, Zhou CW, Zhu GQ, Li N, Qian XL, Chong HH, Yang C, Zeng MS. A multidimensional nomogram combining imaging features and clinical factors to predict the invasiveness and metastasis of combined hepatocellular cholangiocarcinoma. Ann Transl Med 2021;9:1518. [PMID: 34790724 DOI: 10.21037/atm-21-2500] [Reference Citation Analysis]
7 Jiang H, Song B, Qin Y, Chen J, Xiao D, Ha HI, Liu X, Oloruntoba-Sanders O, Erkanli A, Muir AJ, Bashir MR. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol 2021;31:3638-48. [PMID: 33245494 DOI: 10.1007/s00330-020-07488-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018. Korean J Radiol 2021;22:1066-76. [PMID: 33739633 DOI: 10.3348/kjr.2020.0846] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Öcal O, Zech CJ, Fabritius MP, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Berg T, Sengel C, Bargellini I, Iezzi R, Benito A, Pech M, Gasbarrini A, Sangro B, Malfertheiner P, Ricke J, Seidensticker M. Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression. Eur Radiol 2022. [PMID: 35881180 DOI: 10.1007/s00330-022-09000-1] [Reference Citation Analysis]
10 Yao S, Wei Y, Ye Z, Chen J, Duan T, Zhang Z, Song B. Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging. J Magn Reson Imaging 2021. [PMID: 34121266 DOI: 10.1002/jmri.27783] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zheng W, Huang H, She D, Xiong M, Chen X, Lin X, Cao D. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M. Abdom Radiol (NY) 2022;47:957-68. [PMID: 34964069 DOI: 10.1007/s00261-021-03380-6] [Reference Citation Analysis]
12 Catania R, Chupetlovska K, Borhani AA, Maheshwari E, Furlan A. Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications. Abdom Radiol (NY) 2021;46:5723-34. [PMID: 34519877 DOI: 10.1007/s00261-021-03270-x] [Reference Citation Analysis]
13 Park JH, Chung YE, Seo N, Choi JY, Park MS, Kim MJ. Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: Diagnostic performance of category-adjusted LR-5 using modified criteria. PLoS One 2020;15:e0242344. [PMID: 33186378 DOI: 10.1371/journal.pone.0242344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Xie S, Zhang Y, Chen J, Jiang T, Liu W, Rong D, Sun L, Zhang L, He B, Wang J. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI? Abdom Radiol (NY) 2022;47:596-607. [PMID: 34773467 DOI: 10.1007/s00261-021-03339-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Kierans AS, Song C, Gavlin A, Roudenko A, Lu L, Askin G, Hecht EM. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma. AJR Am J Roentgenol 2020;215:1085-92. [PMID: 32877248 DOI: 10.2214/AJR.20.22772] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Kim DH, Choi SH, Park SH, Kim KW, Byun JH, Kim SY, Lee SS, Shin YM, Won HJ, Kim P. Liver imaging reporting and data system category M: A systematic review and meta‐analysis. Liver Int 2020;40:1477-87. [DOI: 10.1111/liv.14420] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Kim DH, Choi SH, Park SH, Kim KW, Byun JH, Kim SY, Lee SS, Choi JI. The Liver Imaging Reporting and Data System tumor-in-vein category: a systematic review and meta-analysis. Eur Radiol 2021;31:2497-506. [PMID: 33001305 DOI: 10.1007/s00330-020-07282-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
18 van der Pol CB, Dhindsa K, Shergill R, Zha N, Ferri M, Kagoma YK, Lee SY, Satkunasingham J, Wat J, Tsai S. MRI LI-RADS Version 2018: Impact of and Reduction in Ancillary Features. AJR Am J Roentgenol 2021;216:935-42. [PMID: 33534620 DOI: 10.2214/AJR.20.23031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zhang H, Guo D, Liu H, He X, Qiao X, Liu X, Liu Y, Zhou J, Zhou Z, Liu X, Fang Z. MRI-Based Radiomics Models to Discriminate Hepatocellular Carcinoma and Non-Hepatocellular Carcinoma in LR-M According to LI-RADS Version 2018. Diagnostics 2022;12:1043. [DOI: 10.3390/diagnostics12051043] [Reference Citation Analysis]
20 Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Koda W, Inoue D, Ogi T, Yoshida K, Gabata T. Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic background. Eur Radiol 2020;30:3438-47. [PMID: 32064560 DOI: 10.1007/s00330-020-06687-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
21 Zhao C, Dai H, Shao J, He Q, Su W, Wang P, Tang Q, Zeng J, Xu S, Zhao J, Xiang S. Accuracy of Various Forms of Contrast-Enhanced MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:680691. [PMID: 34950573 DOI: 10.3389/fonc.2021.680691] [Reference Citation Analysis]
22 Park SH, Shim YS, Kim B, Kim SY, Kim YS, Huh J, Park JH, Kim KW, Lee SS. Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid-enhanced MRI in at-risk patients. Eur Radiol 2021;31:4751-63. [PMID: 33389037 DOI: 10.1007/s00330-020-07577-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Zhou Y, Qin Z, Ding J, Zhao L, Chen Y, Wang F, Jing X. Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis. Front Oncol 2022;12:873913. [PMID: 35425706 DOI: 10.3389/fonc.2022.873913] [Reference Citation Analysis]
24 Lee-Ying R, Ahmed O, Ahmed S, Ahmed S, Bathe OF, Brunet B, Dawson L, Davies J, Gordon V, Hebbard P, Kasnik J, Kim CA, Le D, Lee MKC, Lim H, McGhie JP, Mulder K, Park J, Renouf D, Tam V, Visser R, Wong RPW, Zaidi A, Doll C. Report from the 21st Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; 20-21 September 2019. Curr Oncol 2021;28:3629-48. [PMID: 34590606 DOI: 10.3390/curroncol28050310] [Reference Citation Analysis]
25 Kang JH, Choi SH, Lee JS, Kim KW, Kim SY, Lee SS, Byun JH. Inter-reader reliability of CT Liver Imaging Reporting and Data System according to imaging analysis methodology: a systematic review and meta-analysis. Eur Radiol 2021;31:6856-67. [PMID: 33713172 DOI: 10.1007/s00330-021-07815-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Ghadimi M, Birnbaum J, Kamel IR, Sirlin CB, Chernyak V. What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria? Eur Radiol 2021. [PMID: 34807269 DOI: 10.1007/s00330-021-08389-5] [Reference Citation Analysis]
27 Cunha GM, Tamayo-Murillo DE, Fowler KJ. LI-RADS and transplantation: challenges and controversies. Abdom Radiol (NY) 2021;46:29-42. [PMID: 31696268 DOI: 10.1007/s00261-019-02311-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
28 Tang A, Abukasm K, Moura Cunha G, Song B, Wang J, Wagner M, Dietrich CF, Brancatelli G, Ueda K, Choi JY, Aguirre D, Sirlin CB. Imaging of hepatocellular carcinoma: a pilot international survey. Abdom Radiol (NY) 2021;46:205-15. [PMID: 32488557 DOI: 10.1007/s00261-020-02598-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Hu YX, Shen JX, Han J, Mao SY, Mao RS, Li Q, Li F, Guo ZX, Zhou JH. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS. Front Oncol 2021;11:641195. [PMID: 33912456 DOI: 10.3389/fonc.2021.641195] [Reference Citation Analysis]
30 Lee S, Kim YY, Shin J, Hwang SH, Roh YH, Chung YE, Choi JY. CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. J Am Coll Radiol 2020;17:1199-206. [PMID: 32640250 DOI: 10.1016/j.jacr.2020.06.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
31 Chernyak V. Editorial for "Diagnostic Performance of Liver Imaging Reporting and Data System Version 2017 Versus Version 2018 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Comparative Studies". J Magn Reson Imaging 2021;54:1920-1. [PMID: 34155706 DOI: 10.1002/jmri.27797] [Reference Citation Analysis]
32 Lv K, Cao X, Du P, Fu JY, Geng DY, Zhang J. Radiomics for the detection of microvascular invasion in hepatocellular carcinoma. World J Gastroenterol 2022; 28(20): 2176-2183 [DOI: 10.3748/wjg.v28.i20.2176] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Laroia ST, Yadav K, Rastogi A, Kumar G, Kumar S, Sarin SK. Diagnostic efficacy of dynamic liver imaging using qualitative diagnostic algorithm versus LI-RADS v2018 lexicon for atypical versus classical HCC lesions: A decade of experience from a tertiary liver institute. Eur J Radiol Open 2020;7:100219. [PMID: 32083152 DOI: 10.1016/j.ejro.2020.100219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Liu X, Ni X, Li Y, Yang C, Wang Y, Ma C, Zhou C, Lu X. Diagnostic Performance of LI-RADS Version 2018 for Primary Liver Cancer in Patients With Liver Cirrhosis on Enhanced MRI. Front Oncol 2022;12:934045. [DOI: 10.3389/fonc.2022.934045] [Reference Citation Analysis]
35 Kim YY, Lee S, Shin J, Son WJ, Shin H, Lee JE, Hwang JA, Chung YE, Choi JY, Park MS. Diagnostic Performance of Liver Imaging Reporting and Data System Version 2017 Versus Version 2018 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Comparative Studies. J Magn Reson Imaging 2021. [PMID: 33929784 DOI: 10.1002/jmri.27664] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Zou X, Luo Y, Morelli JN, Hu X, Shen Y, Hu D. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018. Abdom Radiol (NY) 2021;46:3168-78. [PMID: 33660040 DOI: 10.1007/s00261-021-02996-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Jeon SK, Lee JM, Joo I, Yoo J, Park JY. Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates. Eur Radiol 2020;30:4762-71. [PMID: 32333148 DOI: 10.1007/s00330-020-06881-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Kanmaniraja D, Dellacerra G, Holder J, Erlichman D, Chernyak V. Liver Imaging Reporting and Data System (LI-RADS) v2018: Review of the CT/MRI Diagnostic Categories. Can Assoc Radiol J 2021;72:142-9. [PMID: 32063008 DOI: 10.1177/0846537119888393] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Bae JS, Lee JM, Jeon SK, Yoo J, Park SJ, Yoon JH, Joo I, Lee KB, Kim H. LI-RADS Tumor in Vein at CT and Hepatobiliary MRI. Radiology 2021;:210215. [PMID: 34581625 DOI: 10.1148/radiol.2021210215] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Jiang H, Song B, Qin Y, Wei Y, Konanur M, Wu Y, Zaki IH, McInnes MDF, Lafata KJ, Bashir MR. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity. J Magn Reson Imaging 2021. [PMID: 34236120 DOI: 10.1002/jmri.27824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]